CD8+T cell-specific induction of NKG2D receptor by doxorubicin plus interleukin-12 and its contribution to CD8+T cell accumulation in tumors

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Hu, Jiemiao ^a   Zhu, Shiguo ^b   Xia, Xueqing ^a   Zhang, Liangfang ^c   Kleinerman, Eugenie S ^a   Li, Shulin ^a,d  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

Doxorubicin; Interleukin 12; NKG2D+CD8+T cells; Tumor infiltrating lymphocytes

Indexed keywords

BLOCKING ANTIBODY; DOXORUBICIN; INTERLEUKIN 12; NATURAL KILLER CELL RECEPTOR NKG2D; NKG2D BLOCKING ANTIBODY; PLASMID DNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; ELECTROPORATION; FEMALE; FLOW CYTOMETRY; IMMUNOCOMPETENT CELL; IMMUNOFLUORESCENCE; IMMUNOSURVEILLANCE; IN VIVO STUDY; LUNG METASTASIS; LYMPHOCYTE MIGRATION; MONOTHERAPY; MOUSE; NATURAL KILLER CELL; NONHUMAN; PROTEIN EXPRESSION; T CELL DEPLETION; TUMOR LOCALIZATION;

MURINAE; MUS;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CD8-POSITIVE T-LYMPHOCYTES; DOXORUBICIN; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENETIC THERAPY; IMMUNOTHERAPY; INTERLEUKIN-12; LYMPHOCYTES, TUMOR-INFILTRATING; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; PLASMIDS;

EID: 84896727863     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-34     Document Type: Article

References (50)

1. Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, Meatchi T, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Galon J. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005, 353(25):2654-2666. 10.1056/NEJMoa051424, 16371631.
2. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pages F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313(5795):1960-1964. 10.1126/science.1129139, 17008531.
3. Pages F, Galon J, Dieu-Nosjean MC, Tartour E, Sautes-Fridman C, Fridman WH. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 2010, 29(8):1093-1102. 10.1038/onc.2009.416, 19946335.
4. Rody A, Holtrich U, Pusztai L, Liedtke C, Gaetje R, Ruckhaeberle E, Solbach C, Hanker L, Ahr A, Metzler D, Engels K, Karn T, Kaufmann M. T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res 2009, 11(2):R15. 10.1186/bcr2234, 2688939, 19272155.
5. Hiraoka K, Miyamoto M, Cho Y, Suzuoki M, Oshikiri T, Nakakubo Y, Itoh T, Ohbuchi T, Kondo S, Katoh H. Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer 2006, 94(2):275-280. 10.1038/sj.bjc.6602934, 2361103, 16421594.
6. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, Kepner J, Odunsi T, Ritter G, Lele S, Chen YT, Ohtani H, Old LJ, Odunsi K. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005, 102(51):18538-18543. 10.1073/pnas.0509182102, 1311741, 16344461.
7. Clemente CG, Mihm MC, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996, 77(7):1303-1310. 10.1002/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5, 8608507.
8. Nausch N, Cerwenka A. NKG2D ligands in tumor immunity. Oncogene 2008, 27(45):5944-5958. 10.1038/onc.2008.272, 18836475.
9. Ramakrishnan R, Assudani D, Nagaraj S, Hunter T, Cho HI, Antonia S, Altiok S, Celis E, Gabrilovich DI. Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest 2010, 120(4):1111-1124. 10.1172/JCI40269, 2846048, 20234093.
10. Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 2011, 8(3):151-160. 10.1038/nrclinonc.2010.223, 21364688.
11. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003, 348(3):203-213. 10.1056/NEJMoa020177, 12529460.
12. Zhu S, Waguespack M, Barker SA, Li S. Doxorubicin directs the accumulation of interleukin-12 induced IFN gamma into tumors for enhancing STAT1 dependent antitumor effect. Clin Cancer Res 2007, 13(14):4252-4260. 10.1158/1078-0432.CCR-06-2894, 17634555.
13. Ljunggren HG. Cancer immunosurveillance: NKG2D breaks cover. Immunity 2008, 28(4):492-494. 10.1016/j.immuni.2008.03.007, 18400193.
14. Wu J, Song Y, Bakker AB, Bauer S, Spies T, Lanier LL, Phillips JH. An activating immunoreceptor complex formed by NKG2D and DAP10. Science 1999, 285(5428):730-732. 10.1126/science.285.5428.730, 10426994.
15. Raulet DH. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 2003, 3(10):781-790. 10.1038/nri1199, 14523385.
16. Vivier E, Tomasello E, Paul P. Lymphocyte activation via NKG2D: towards a new paradigm in immune recognition?. Curr Opin Immunol 2002, 14(3):306-311. 10.1016/S0952-7915(02)00337-0, 11973127.
17. Diefenbach A, Jamieson AM, Liu SD, Shastri N, Raulet DH. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat Immunol 2000, 1(2):119-126. 10.1038/77793, 11248803.
18. Ehrlich LI, Ogasawara K, Hamerman JA, Takaki R, Zingoni A, Allison JP, Lanier LL. Engagement of NKG2D by cognate ligand or antibody alone is insufficient to mediate costimulation of human and mouse CD8+ T cells. J Immunol 2005, 174(4):1922-1931.
19. Gilfillan S, Ho EL, Cella M, Yokoyama WM, Colonna M. NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation. Nat Immunol 2002, 3(12):1150-1155. 10.1038/ni857, 12426564.
20. Lodoen MB, Lanier LL. Natural killer cells as an initial defense against pathogens. Curr Opin Immunol 2006, 18(4):391-398. 10.1016/j.coi.2006.05.002, 16765573.
21. Wang E, Selleri S, Marincola FM. The requirements for CTL-mediated rejection of cancer in humans: NKG2D and its role in the immune responsiveness of melanoma. Clin Cancer Res 2007, 13(24):7228-7231. 10.1158/1078-0432.CCR-07-2150, 18094399.
22. Choi BK, Kim YH, Kang WJ, Lee SK, Kim KH, Shin SM, Yokoyama WM, Kim TY, Kwon BS. Mechanisms involved in synergistic anticancer immunity of anti-4-1BB and anti-CD4 therapy. Cancer Res 2007, 67(18):8891-8899. 10.1158/0008-5472.CAN-07-1056, 17875731.
23. Zhang C, Zhang J, Niu J, Zhou Z, Tian Z. Interleukin-12 improves cytotoxicity of natural killer cells via upregulated expression of NKG2D. Hum Immunol 2008, 69(8):490-500. 10.1016/j.humimm.2008.06.004, 18619507.
24. Ho EL, Carayannopoulos LN, Poursine-Laurent J, Kinder J, Plougastel B, Smith HR, Yokoyama WM. Costimulation of multiple NK cell activation receptors by NKG2D. J Immunol 2002, 169(7):3667-3675.
25. Smyth MJ, Swann J, Cretney E, Zerafa N, Yokoyama WM, Hayakawa Y. NKG2D function protects the host from tumor initiation. J Exp Med 2005, 202(5):583-588. 10.1084/jem.20050994, 2212868, 16129707.
26. Smyth MJ, Swann J, Kelly JM, Cretney E, Yokoyama WM, Diefenbach A, Sayers TJ, Hayakawa Y. NKG2D recognition and perforin effector function mediate effective cytokine immunotherapy of cancer. J Exp Med 2004, 200(10):1325-1335. 10.1084/jem.20041522, 2211920, 15545356.
27. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003, 3(2):133-146. 10.1038/nri1001, 12563297.
28. Trinchieri G. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 1994, 84(12):4008-4027.
29. Li S. IL-12-Based therapy of malignancies. Drugs Today (Barc) 2001, 37(9):629-637.
30. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004, 56(2):185-229. 10.1124/pr.56.2.6, 15169927.
31. Karimi M, Cao TM, Baker JA, Verneris MR, Soares L, Negrin RS. Silencing human NKG2D, DAP10, and DAP12 reduces cytotoxicity of activated CD8+ T cells and NK cells. J Immunol 2005, 175(12):7819-7828.
32. Markiewicz MA, Wise EL, Buchwald ZS, Pinto AK, Zafirova B, Polic B, Shaw AS. RAE1epsilon ligand expressed on pancreatic islets recruits NKG2D receptor-expressing cytotoxic T cells independent of T cell receptor recognition. Immunity 2012, 36(1):132-141. 10.1016/j.immuni.2011.11.014, 3276246, 22244846.
33. Diefenbach A, Jensen ER, Jamieson AM, Raulet DH. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 2001, 413(6852):165-171. 10.1038/35093109, 3900321, 11557981.
34. Jamieson AM, Diefenbach A, McMahon CW, Xiong N, Carlyle JR, Raulet DH. The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity 2002, 17(1):19-29. 10.1016/S1074-7613(02)00333-3, 12150888.
35. Zhang T, Sentman CL. Mouse tumor vasculature expresses NKG2D ligands and can be targeted by chimeric NKG2D-modified T cells. J Immunol 2013, 190(5):2455-2463. 10.4049/jimmunol.1201314, 23355740.
36. Musha H, Ohtani H, Mizoi T, Kinouchi M, Nakayama T, Shiiba K, Miyagawa K, Nagura H, Yoshie O, Sasaki I. Selective infiltration of CCR5(+)CXCR3(+) T lymphocytes in human colorectal carcinoma. Int J Cancer 2005, 116(6):949-956. 10.1002/ijc.21135, 15856455.
37. Lanca T, Costa MF, Goncalves-Sousa N, Rei M, Grosso AR, Penido C, Silva-Santos B. Protective role of the inflammatory CCR2/CCL2 chemokine pathway through recruitment of type 1 cytotoxic gammadelta T lymphocytes to tumor beds. J Immunol 2013, 190(12):6673-6680. 10.4049/jimmunol.1300434, 23686489.
38. Mulligan AM, Raitman I, Feeley L, Pinnaduwage D, Nguyen LT, O'Malley FP, Ohashi PS, Andrulis IL. Tumoral lymphocytic infiltration and expression of the chemokine CXCL10 in breast cancers from the Ontario Familial Breast Cancer Registry. Clin Cancer Res 2013, 19(2):336-346. 10.1158/1078-0432.CCR-11-3314, 3548938, 23213058.
39. Muthuswamy R, Berk E, Junecko BF, Zeh HJ, Zureikat AH, Normolle D, Luong TM, Reinhart TA, Bartlett DL, Kalinski P. NF-kappaB hyperactivation in tumor tissues allows tumor-selective reprogramming of the chemokine microenvironment to enhance the recruitment of cytolytic T effector cells. Cancer Res 2012, 72(15):3735-3743. 10.1158/0008-5472.CAN-11-4136, 3780565, 22593190.
40. Ewens A, Luo L, Berleth E, Alderfer J, Wollman R, Hafeez BB, Kanter P, Mihich E, Ehrke MJ. Doxorubicin plus interleukin-2 chemoimmunotherapy against breast cancer in mice. Cancer Res 2006, 66(10):5419-5426. 10.1158/0008-5472.CAN-05-3963, 16707470.
41. Mattarollo SR, Loi S, Duret H, Ma Y, Zitvogel L, Smyth MJ. Pivotal Role of Innate and Adaptive Immunity in Anthracycline Chemotherapy of Established Tumors. Cancer Res 2011, 71(14):4809-4820. 10.1158/0008-5472.CAN-11-0753, 21646474.
42. Cosman D, Mullberg J, Sutherland CL, Chin W, Armitage R, Fanslow W, Kubin M, Chalupny NJ. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 2001, 14(2):123-133. 10.1016/S1074-7613(01)00095-4, 11239445.
43. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, Spies T. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999, 285(5428):727-729. 10.1126/science.285.5428.727, 10426993.
44. Coleman M, Muller S, Quezada A, Mendiratta SK, Wang J, Thull NM, Bishop J, Matar M, Mester J, Pericle F. Nonviral interferon alpha gene therapy inhibits growth of established tumors by eliciting a systemic immune response. Hum Gene Ther 1998, 9(15):2223-2230. 10.1089/hum.1998.9.15-2223, 9794206.
45. Puisieux I, Odin L, Poujol D, Moingeon P, Tartaglia J, Cox W, Favrot M. Canarypox virus-mediated interleukin 12 gene transfer into murine mammary adenocarcinoma induces tumor suppression and long-term antitumoral immunity. Hum Gene Ther 1998, 9(17):2481-2492. 10.1089/hum.1998.9.17-2481, 9853515.
46. Li S, Xia X, Zhang X, Suen J. Regression of tumors by IFN-alpha electroporation gene therapy and analysis of the responsible genes by cDNA array. Gene Ther 2002, 9(6):390-397. 10.1038/sj.gt.3301645, 11960315.
47. Reed SD, Fulmer A, Buckholz J, Zhang B, Cutrera J, Shiomitsu K, Li S. Bleomycin/interleukin-12 electrochemogenetherapy for treating naturally occurring spontaneous neoplasms in dogs. Cancer Gene Ther 2010, 17(8):571-578. 10.1038/cgt.2010.13, 20414325.
48. Walzer T, Blery M, Chaix J, Fuseri N, Chasson L, Robbins SH, Jaeger S, Andre P, Gauthier L, Daniel L, Chemin K, Morel Y, Dalod M, Imbert J, Pierres M, Moretta A, Romagne F, Vivier E. Identification, activation, and selective in vivo ablation of mouse NK cells via NKp46. Proc Natl Acad Sci USA 2007, 104(9):3384-3389. 10.1073/pnas.0609692104, 1805551, 17360655.
49. Li S, Zhang X, Xia X. Regression of tumor growth and induction of long-term antitumor memory by interleukin 12 electro-gene therapy. J Natl Cancer Inst 2002, 94(10):762-768. 10.1093/jnci/94.10.762, 12011227.
50. Li S, Zhang X, Xia X, Zhou L, Breau R, Suen J, Hanna E. Intramuscular electroporation delivery of IFN-alpha gene therapy for inhibition of tumor growth located at a distant site. Gene Ther 2001, 8:400-407. 10.1038/sj.gt.3301418, 11313817.